Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will hold its fourth-quarter earnings call on February 28, 2023, at 4:30 PM ET, following the earnings release after market close on the same day. The call will provide a financial overview and update on company performance for the quarter ending December 31, 2022. Interested parties can participate via a dial-in number or watch a live webcast on the company's website.

Myriad Genetics specializes in genetic testing and precision medicine, offering tests that inform disease risk assessment and treatment decisions, enhancing patient care and reducing healthcare costs.

Positive

• Upcoming earnings call on February 28, 2023, providing crucial financial updates.
• Focus on genetic testing and precision medicine supports potential growth opportunities.

Negative

• None.

SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on Tuesday, Feb. 28, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes.

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the period ending Dec. 31, 2022.

The dial-in number for domestic callers is 1-800-920-6941. International callers may dial 1-212-231-2939. All callers will be asked to reference reservation number 22025948. An archived replay of the call will be available for seven days by dialing 1-800-257-4607 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.  

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2023 Myriad Genetics, Inc. All rights reserved. 

Media Contact:
Glenn Farrell
(801) 584-1153
Glenn.Farrell@myriad.com

Investor Contact:
Matt Scalo
(801) 584-3532
Matt.Scalo@myriad.com

FAQ

When will Myriad Genetics release its Q4 earnings for 2022?

Myriad Genetics will release its Q4 earnings for 2022 on February 28, 2023.

What time is the Myriad Genetics earnings conference call?

The earnings conference call for Myriad Genetics is scheduled for 4:30 PM ET on February 28, 2023.

How can I participate in the Myriad Genetics earnings call?

You can participate in the Myriad Genetics earnings call by dialing 1-800-920-6941 for domestic calls or 1-212-231-2939 for international calls.

What is the focus of Myriad Genetics as a company?

Myriad Genetics specializes in genetic testing and precision medicine, helping assess disease risk and guide treatment decisions.